LABCORP IS SCHEDULED TO PRSENT AT THE MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE

On August 29, 2019 LabCorp (NYSE: LH) reported it will participate at the Morgan Stanley Global Healthcare Conference (Press release, LabCorp, AUG 29, 2019, View Source [SID1234539112]). LabCorp’s presentation is planned for Monday, Sept. 9, 2019 at 9:55 a.m. ET.
A live audio webcast will be available via the Company website at www.LabCorp.com and archived for replay.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Eiger BioPharmaceuticals to Participate in September Conferences

On August 29, 2019 Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, reported that management will participate in the following upcoming investor conferences in September (Press release, Eiger Biopharmaceuticals, AUG 29, 2019, View Source [SID1234539129]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Baird 2019 Global Healthcare Conference at the InterContinental Barclay in New York City. Eiger will present a corporate update with a live webcast on September 4, 9:05-9:35 PM ET. Eiger will host one-on-one meetings.
CITI 14th Annual Biotech Conference at the Four Seasons Hotel in Boston on September 5. Eiger will host one-on-one meetings.
H.C. Wainwright Global Investment Conference at the Lotte New York Hotel in New York City. Eiger will present a corporate update with a live webcast on September 10, 3:00-3:25 PM ET. Eiger will host one-on-one meetings.
Ladenburg Thalmann 2019 Healthcare Conference at Sofitel Hotel in New York City. Eiger will present a corporate update with a live webcast on September 24, 12:00-12:25 PM ET. Eiger will host one-on-one meetings.
The live webcast of the Baird, H.C. Wainwright, and Ladenburg presentations will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab. A replay of the webcast will be available approximately one hour following the live event.

Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

On August 29, 2019 Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer and other indications, reported that members of the management team will participate in the following upcoming investor conferences (Press release, Pieris Pharmaceuticals, AUG 29, 2019, View Source [SID1234539113]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 14th Annual Biotech Conference

Wednesday, September 4, 2019 at the Four Seasons Hotel in Boston. The Company will conduct one-on-one meetings with institutional investors at this conference.

Baird 2019 Global Healthcare Conference

Thursday, September 5, 2019 at 2:00PM EDT at the InterContinental New York Barclay Hotel in New York City. A webcast of the Company’s presentation will be available at this link.

H.C. Wainwright 21st Annual Global Investment Conference

Monday, September 9, 2019 at 9:10AM EDT at the Lotte New York Palace Hotel in New York City. A webcast of the Company’s presentation will be available at this link.

CryoLife to Participate in Upcoming Investor Conferences

On August 29, 2019 CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, reported that it will participate in two upcoming investor conferences (Press release, CryoLife, AUG 29, 2019, View Source [SID1234539130]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CryoLife’s management will be presenting at the Morgan Stanley 17th Annual Healthcare Conference in New York, New York on Wednesday, September 11, 2019 at 11:40 a.m. ET and will feature an overview of the company by Pat Mackin, Chairman, President and Chief Executive Officer. The live webcast can be accessed through CryoLife’s website, www.cryolife.com, on the Investor Relations page. An archived copy of the webcast will be available for 90 days on the same website.

CryoLife’s management will also be participating in investor meetings at the Lake Street 3rd Annual B.I.G. Conference in New York, New York on Thursday, September 12, 2019. Due to the format of this event no webcast will be available.

QIMR Berghofer’s world leading research recognised with record federal funding

On August 29, 2019 QIMR Berghofer scientists reported have been awarded almost $16 million in the latest round of federal grant funding to progress their vital research into improving the health of Australians (Press release, QIMR Berghofer Medical Research Institute, AUG 29, 2019, View Source [SID1234539114]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Federal Health Minister Greg Hunt has reported the recipients of Investigator Grants from the National Health and Medical Research Council (NHMRC).

QIMR Berghofer scientists secured nine Investigator Grants to explore a diverse range of research, including genetic risk factors of diseases and disorders, improving cancer outcomes, and the study of infectious diseases.

Professor Nick Martin has been awarded more than $3 million to find the genetic causes of mental health problems and translate those findings to preventative measures, with the hope it will ease the burden on Medicare and the Pharmaceutical Benefits Scheme.

Professor Sarah Medland has received $1.6 million to advance our understanding of psychiatric disorders by studying brain imaging and genetics.

Professor Andreas Suhrbier will use his $2.5 million grant to develop interventions for Zika virus and chikungunya virus.

Professor Mark Smyth has been given the highest grant rating, and secured $2.1 million to find new methods to improve cancer immunotherapy.

Professor Amanda Spurdle has received $2.1 million to improve the diagnosis, prevention, and treatment of hereditary cancer and other diseases.

Professor Penelope Webb has been awarded $1.85 million to study how to improve people’s prospects of surviving cancer.

QIMR Berghofer’s Director and CEO, Professor Frank Gannon, said the Institute’s success in securing limited federal research funds reaffirmed its position as a leader in medical research in the country.

"I’m pleased to see five of the nine awards going to female scientists to lead innovative research projects at the Institute, reaffirming the important role women play at QIMR Berghofer," Professor Gannon said.

"It’s also great to see three of our emerging talents in the field of genetics, Doctor Tracy O’Mara, Doctor Katrina Grasby and Doctor Puya Gharahkhani, awarded Emerging Leadership Grants.

"The funding environment for medical research is becoming more competitive and it’s encouraging that our Institute has done so well to secure the highest funding in the state after the University of Queensland and to be the second most successful Medical Research Institute in the country."

Investigator Grant winners:

Professor Sarah Medland – Advancing our understanding of Psychiatric Disorders through Imaging and Genetics.

Professor Nicholas Martin – Adding value to Medicare/PBS to find the genetic causes of mental health problems and translate this to preventive measures.

Doctor Puya Gharahkhani – Identifying the contribution of phenotypic and genetic risk factors for complex traits, with implication to risk prediction and causal inference.

Doctor Tracy O’Mara – Leveraging genetic data to understand endometrial cancer.

Professor Penelope Webb – Enhancing cancer survivorship.

Doctor Katrina Grasby – Effects of structural, mitochondrial, and X chromosome variants on brain structure.

Professor Andreas Suhrbier – Developing interventions for chikungunya and Zika virus.

Professor Mark Smyth – New methods to improve cancer immunotherapy.

Professor Amanda Spurdle – Improving diagnosis, prevention, and treatment of hereditary cancer and other diseases.